




A GENE EXPRESSION-BASED TEST

PUBLICATIONS

merlinmelanomatest.com



Publications

Validation studies

Validation of a clinicopathological and gene expression profile model to identify patients with cutaneous melanoma where sentinel lymph node biopsy is unnecessary.

[Read More](#)

Johansson et al. 2021. European Journal of Surgical Oncology.

Validation of CP-GEP (Merlin Assay) for predicting sentinel lymph node metastasis in primary cutaneous melanoma patients: a U.S. cohort study.

[Read More](#)

Yousaf et al. 2021. International Journal of Dermatology.

Validation of a clinicopathological and gene expression profile model for sentinel lymph node metastasis in primary cutaneous melanoma.

[Read More](#)

Mulder et al. 2020. British Journal of Dermatology.

Clinical utility studies

Cost evaluation of the Merlin assay for predicting melanoma sentinel lymph node biopsy metastasis.

[Read More](#)

Thao et al. 2022. International Journal of Dermatology.

Using the Merlin Assay for reducing sentinel lymph node biopsy complications in melanoma: a retrospective cohort study.

[Read More](#)

Hieken et al. 2022. International Journal of Dermatology.

Deselecting melanoma patients for sentinel lymph node biopsy during COVID-19: clinical utility of tumor molecular profiling.

[Read More](#)

Meves & Eggermont 2020. Mayo Clin Proc Inn Qual Out.

Primary cutaneous melanoma risk stratification using a clinicopathologic and gene expression model: a pilot study.

[Read More](#)

Arias-Mejias et al. 2020. International Journal of Dermatology.

Discovery study

Model combining tumor molecular and clinicopathologic risk factors predicts sentinel lymph node metastasis in primary cutaneous melanoma.

[Read More](#)

Bellomo et al. 2020. JCO Precision Oncology.



Merlin at conferences & meetings

Prospective studies

MERLIN_001: A prospective registry study of a primary melanoma gene signature to predict sentinel node (SN) status and determine its prognostic value for more accurate staging of SN-negative melanoma patients. [Read More](#)
Hieken et al. 2022. ASCO Conference.

Use of CP-GEP to identify primary cutaneous melanoma patients with low risk for SN metastasis in a prospective multicenter Dutch study during COVID-19. [Read More](#)
Stassen et al. 2022. EADO Conference.

Use of Merlin Assay to identify patients with a low-risk for SN metastasis in a prospective multicenter Dutch study of a primary melanoma gene-signature (CP-GEP model) to predict sentinel node status during COVID-19. [Read More](#)
Stassen et al. 2022. ASCO Conference.

Using the clinicopathologic and gene expression (CP-GEP) model to predict sentinel node status in patients with primary melanoma: a prospective cohort study during the COVID-19 pandemic. [Read More](#)
Mulder et al. 2021. EADO Conference.

Validation studies

Independent validation study of CP-GEP model (Merlin Assay) to identify patients who can safely forgo sentinel lymph node biopsy. [Read More](#)
Johansson et al. 2021. EADO Conference.

Validation of a Model Combining Clinicopathologic Risk Factors and a Gene Expression Profile to Identify Primary Melanoma Patients Who Can Safely Forgo Sentinel Lymph Node Biopsy. [Read More](#)
Yousaf et al. 2020. ESMO Conference.

Validation of a ClinicoPathological and Gene Expression Profile (CP-GEP) model for sentinel lymph node metastasis in primary cutaneous melanoma. [Read More](#)
Mulder et al. 2019. ESMO Conference.

Clinical utility studies

Cutaneous melanoma patients with minimal SN tumor burden: CP-GEP (Merlin Assay) may guide decision-making beyond nodal assessment. [Read More](#)
Tjien-Fooh et al. 2022. AAD Conference.

The use of a clinicopathologic and gene expression model (Merlin Assay) to risk stratify cutaneous melanoma patients in clinical practice: A pilot study. [Read More](#)
Bridges et al. 2020. ASDP Conference.

Discovery

A combined clinicopathologic and gene expression model (CP-GEP) identifies primary cutaneous melanoma patients who can safely forgo sentinel lymph node biopsy. [Read More](#)
Meves et al. 2020. AAD Conference.

A molecular model to identify patients who can safely forgo sentinel lymph node biopsy in primary cutaneous melanoma. [Read More](#)
Bellomo et al. 2019. CIM Conference.

Stromal gene expression predicts sentinel lymph node metastasis of primary cutaneous melanoma. [Read More](#)
Somnidi-Damodaran et al. 2019. EADO conference.